Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Use of Pemigatinib to Treat a Single Patient With Mixed Phenotype Acute Leukemia, B/Myeloid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03906357
Expanded Access Status : No longer available
First Posted : April 8, 2019
Last Update Posted : April 9, 2019
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Tracking Information
First Submitted Date April 4, 2019
First Posted Date April 8, 2019
Last Update Posted Date April 9, 2019
 
Descriptive Information
Brief Title Expanded Access Use of Pemigatinib to Treat a Single Patient With Mixed Phenotype Acute Leukemia, B/Myeloid
Official Title Not Provided
Brief Summary Expanded access use of Pemigatinib to treat a single patient with mixed phenotype acute leukemia, B/myeloid.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Not Provided
Intervention Drug: Pemigatinib
Other Name: INCB054828
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-

Sex/Gender Not Provided
Ages Child, Adult, Older Adult
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number NCT03906357
Other Study ID Numbers I-54828-19-01
Responsible Party Incyte Corporation
Study Sponsor Incyte Corporation
Collaborators Not Provided
Investigators
Principal Investigator: Ellen Ritchie, MD Weill Cornell Medical College-New York Presbyterian Hospital
PRS Account Incyte Corporation
Verification Date April 2019